Printer Friendly

COMPUMED ACQUIRES RIGHTS TO DETOXAHOL; NEW DRUG TO LOWER BLOOD ALCOHOL CONTENT

 MANHATTAN BEACH, Calif., Dec. 7 /PRNewswire/ -- CompuMed, Inc. (NASDAQ: CMPD) today announced it has acquired an option for the rights to a new drug called Detoxahol from MGB Nutraceuticals, Inc. Detoxahol is a substance that facilitates the rapid lowering of blood alcohol from people who have been drinking alcohol.
 Detoxahol is currently under development at a major university, which has received a grant from the National Institutes of Health (NIH) to fund the project. CompuMed has a contract with MGB Nutraceuticals, a corporation that established the original relationship with the university. Under the terms of this agreement, CompuMed obtained the rights to Detoxahol for a royalty fee, plus CompuMed stock. The amount of stock is based on CompuMed's stock performance; under this agreement, MGB Nutraceuticals could become a majority shareholder of CompuMed's stock.
 "There are currently no other pharmaceutical methods of removing alcohol from the blood," said Howard Mark, M.D., medical director and board member of CompuMed and principal officer of MGB Nutraceuticals. "We believe that with Detoxahol, we are creating a new type of pharmaceutical to meet an enormous worldwide need. This is a substance that has exciting possible applications for emergency rooms, ambulances, and over-the-counter use."
 Detoxahol augments the liver's natural function of removing alcohol from the blood by creating an "auxiliary liver function" in the small intestine. Its efficacy depends on the amount of Detoxahol taken compared to the amount of alcohol consumed; since large doses of Detoxahol can be taken, alcohol detoxification could occur quickly.
 "CompuMed has always been committed to producing timely, effective products that address crucial needs," said Dr. Mark. "We believe that Detoxahol is a drug with enormous potential to help solve one of society's leading problems. Much like our bone density test for osteoporosis, the OsteoGram(TM), Detoxahol is a product which could save the healthcare system vast sums of money; more importantly, it could save lives."
 Detoxahol should have no negative side effects, since all of the metabolic end products already occur naturally in the body. The potential markets for Detoxahol include medically supervised use in hospital emergency rooms (where approximately 10 percent to 20 percent of the 90 million annual visits are related to alcohol) and ambulances, plus an over-the-counter version that could be sold in bars and supermarkets. Pre-clinical testing for Detoxahol has been completed, and CompuMed hopes to begin clinical trials in early 1994.
 "Detoxahol is an exciting new drug for CompuMed," said Dr. Mark. "It addresses a new research area for the company, and it is consistent with CompuMed's commitment to providing high-quality, practical solutions for important health problems."
 MGB Nutraceuticals is a corporation formed to locate unique new medical products with high commercial potential. It seeks to acquire the rights to these products, place them with suitable companies, and arrange for the financing needed to develop them and bring the products to market.
 CompuMed, based in Manhattan Beach, is focused primarily on bone density testing and computer interpretation of electrocardiograms (ECGs). The company currently markets a product called OsteoGram that measures bone mineral density from hand X-rays as an indicator of osteoporosis, and its ECG services are provided to about 1,800 doctors and healthcare facilities. CompuMed has established a marketing partnership for OsteoGram with Rhone-Poulenc Rorer, the world's eighth largest pharmaceutical company, and a testing program for OsteoGram with Merck, the world's largest pharmaceutical company.
 For additional information:
 Call the fax-on-demand number -- In Manhattan: 696-4455, ext. 329; Outside Manhattan: 1-212-696-4455, ext. 329.
 Remember to enter code 110 when asked about what documents you want.
 When leaving your fax number: Omit the (212) area code if you are in Manhattan.
 Include "1" before area code for all other locations.
 -0- 12/7/93
 /CONTACT: Anthony J. Russo, Ph.D., of Noonan/Russo Communications, 212-696-4455, ext. 202/
 (CMPD)


CO: CompuMed, Inc.; MGB Nutraceuticals, Inc. ST: California IN: MTC SU:

GK-TW -- NY011 -- 1176 12/07/93 09:43 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Dec 7, 1993
Words:652
Previous Article:BUNKER HILL INCOME SECURITIES, INC. BOARD REVISES PLAN OF REORGANIZATION
Next Article:FDA APPROVES GAMIMUNE N IN THE TREATMENT 0F PEDIATRIC AIDS AND BONE MARROW TRANSPLANT PATIENTS
Topics:

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters